Twenty adult Indian patients suffering from the spastic form of irritable colon, i.e. abdominal pain and constipation, were given trimebutine (Mebutin), 2-phenyl, 2-dimethylamino-n-butyl 3, 4, 5-trimethoxybenzoate. Patients were given treatment with 200 mg trimebutine three times daily, or placebo for 4 weeks, and then crossed over. In addition, stool transit times were assessed by the single stool transit time (SST) method of Cummings. Results showed a statistical improvement in abdominal pain and constipation with both trimebutine and placebo after 4 weeks, but only with trimebutine after 8 weeks. Single stool transit time was significantly reduced after trimebutine.
Get full access to this article
View all access options for this article.
References
1.
Beecham Pharmaceuticals (1978) Personal communication.
2.
CamatteRSarlesH (1971) Appreciation of the therapeutic effects of a novel antispasmodic, trimebutine. Gazette Medicate de France Suppl. 30th October.
3.
ChowdhuryA RDinosoV PLorberS H (1976) Characterization of a hyperactive segment of the rectosigmoid junction. Gastroenterology71, 584.
4.
CummingsJ HWigginsH S (1976) Transit through the gut measured by analysis of a single stool. Gut17, 219.
5.
KirsnerJ BPalmerW L (1958) The irritable colon. Gastroenterology34, 490.
6.
MoctezumaU M (1977) Trimebutine in the treatment of the irritable colon. Investigación Médica Internacional4, 71.
7.
SnapeW J (1977) Evidence that abnormal myoelectrical activity produces colonic dysfunction in the irritable bowel syndrome. Gastroenterology72, 383.
8.
TrueloveS C (1966) Movement of the large intestine. Physiological Reviews46, 457.
